Fetomaternal Outcomes and Response to Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy: A Prospective Observational Study from Eastern India
Background: Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder characterized by pruritus and elevated serum bile acid levels, associated with adverse fetal outcomes including preterm delivery and intrauterine fetal death. Ursodeoxycholic acid (UDCA) is widely used for management, but regional data on fetomaternal outcomes and treatment response remain limited in Eastern India. This study aimed to evaluate clinical profile, biochemical parameters, fetomaternal outcomes, and response to UDCA therapy in patients with ICP.Methods: A prospective observational study was conducted among 60 pregnant women diagnosed with ICP at a tertiary care medical college in Eastern India between January 2023 and December 2024. Diagnosis was based on pruritus with serum bile acid levels >10 µmol/L and abnormal liver function tests after exclusion of other causes. Clinical characteristics, biochemical parameters, and pregnancy outcomes were recorded. UDCA was administered at a dose of 10–15 mg/kg/day until delivery. Data were analyzed using descriptive statistics, and appropriate paired statistical test was applied to assess treatment response. A p value <0.05 was considered statistically significant.Results: The mean maternal age was 29.88 ± 4.06 years. The mean gestational age at onset of pruritus was 32.07 ± 2.00 weeks, indicating predominant third-trimester presentation. Mean serum bile acid level was 21.03 ± 12.18 µmol/L (range: 12.8–63.7 µmol/L). Mean alanine aminotransferase and aspartate aminotransferase levels were 205.22 ± 84.00 IU/L and 171.42 ± 59.55 IU/L, respectively. Preterm delivery occurred in 30% of cases, and cesarean section rate was 40%. Improvement in pruritus and biochemical parameters was observed in 44 (73.3%) patients following UDCA therapy. Clinical and biochemical improvement was statistically significant (p < 0.05).Conclusion: ICP is associated with significant biochemical abnormalities and adverse pregnancy outcomes. Serum bile acid levels are an important predictor of fetal risk. UDCA therapy is associated with improvement in maternal symptoms and biochemical parameters. Early diagnosis, close monitoring, and timely delivery are essential to improve fetomaternal outcomes.